FibroBiologics, Inc. (EXCHANGE:FBLG) reported an insider purchase by General Counsel Garcia Ruben A, who acquired 40,000 shares of the company’s common stock on February 27, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The shares were bought in multiple transactions at prices ranging from $0.3221 to $0.3268 per share, producing an average price of $0.3264 and a total outlay of $13,056. After completing these purchases, Garcia Ruben A directly holds 180,000 shares of FibroBiologics.
This insider buying comes amid notable recent activity for the company’s stock. Shares of FBLG have jumped roughly 30% over the last week, though they remain approximately 74% below their level a year ago. Analytics from InvestingPro indicate the stock may be slightly undervalued at current levels, and the service notes that investors can consult an additional set of 13 InvestingPro Tips for further context.
Corporate and clinical developments
Several corporate and clinical updates accompany the insider transaction. FibroBiologics has been awarded a U.S. patent for a fibroblast-based therapy aimed at treating osteoporosis, a development the company describes as advancing its approach to addressing bone disease through fibroblast cell administration.
Shareholders recently approved a reverse stock split and the issuance of warrant shares, as reflected in a separate SEC filing. In parallel, a Nasdaq Hearings Panel has granted the company an extension to meet listing requirements; the company must satisfy specified conditions by deadlines in February and April 2026.
On the clinical front, H.C. Wainwright recently lowered its price target for FibroBiologics to $4.00 but left its Buy rating intact. The equity research firm emphasized the importance of an upcoming Phase 1/2 clinical trial for the company’s CYWC628 therapy, which is being developed to treat diabetic foot ulcers. That trial has received ethics approval in Australia and is planned to commence in the first quarter of 2026.
The Phase 1/2 study is slated to enroll 120 patients across 10 sites. Interim readouts are expected by mid-year, with primary or final results anticipated before the end of 2026.
What remains open
While the insider purchase and recent milestones provide datapoints for investors, several items remain in progress: the company must meet Nasdaq’s specified conditions within the granted extension periods, and the Phase 1/2 trial will need to produce data before the clinical potential of CYWC628 can be assessed. Similarly, the longer-term market reaction to the patent award, corporate recapitalization actions and the research analyst’s revised price target will unfold over time.